Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

World Bank says to commit $2 billion to vaccines in developing countries by end-April

Published 04/09/2021, 05:05 PM
Updated 04/09/2021, 05:55 PM
© Reuters. FILE PHOTO: A participant stands near a logo of World Bank at the International Monetary Fund - World Bank Annual Meeting 2018 in Nusa Dua

By David Lawder

WASHINGTON (Reuters) - The World Bank Group will have committed $2 billion in financing by the end of April for COVID-19 vaccines in some 40 developing countries, World Bank Managing Director of Operations Axel van Trotsenburg said on Friday.

The $2 billion is part of a pool of some $12 billion that the World Bank has made available overall for vaccine development, distribution and production in low-and middle-income countries, van Trotsenburg told a World Bank forum.

David Malpass, the World Bank's president, said in separate remarks (https://www.worldbank.org/en/news/speech/2021/04/09/remarks-by-world-bank-group-president-david-malpass-to-the-spring-meetings-2021-development-committee) to the lender's development committee that the bank expects this to expand to $4 billion worth of commitments in 50 countries by mid-year.

But public health officials at the same forum warned that a race between the coronavirus and the vaccines meant to stop it could be lost if the pace of vaccinations in the developing world did not pick up.

World Health Organization (WHO) director-general Tedros Adhanom Ghebreyesus said that existing vaccines could be rendered ineffective if the virus continues to spread and mutate.

"Even those countries who have high coverage of vaccines will not be secure because the new variants that may not be stopped by the vaccines we have, will invade the countries that may have even 100% coverage in a few months," he said.

Tedros called for more political will to boost production of COVID-19 vaccines and share supplies, including through stalled intellectual property waiver on vaccines through the World Trade Organization.

The WTO's Trade-Related Aspects of Intellectual Property, or TRIPS waiver was the "elephant in the room" holding back vaccine production, Tedros said, adding that it was meant for emergencies such as the coronavirus pandemic.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

"We haven't seen any emergency like this in our lifetime. If we cannot use it now, then when are we going to use it?" Tedros asked. "The mother of all these bottlenecks is lack of political will."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.